Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration

Oncology Letters

Volumn 2, Issue 3, 2011, Pages 483-488

  Rath, Timo ^a   Stöckle, Julia ^a   Roderfeld, Martin ^a   Tschuschner, Annette ^a   Graf, Jürgen ^b,c   Roeb, Elke ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Deutsche Lufthansa AG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Matrix metalloproteinases; Toll like receptors

Indexed keywords

COLLAGENASE 3; CPG OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9;

ARTICLE; CANCER CELL; CELL MIGRATION; COLORECTAL CANCER; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 79953271071     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.276     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Yilmaz M and Christofori G: Mechanisms of motility in metastasizing cells. Mol Cancer Res 8: 629-642, 2010.
3. Shapiro SD: Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 10: 602-608, 1998.
4. Decock J, Paridaens R and Ye S: Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet 73: 197-211, 2008.
5. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
6. Fingleton B: Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 11: 479-491, 2006.
7. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
8. Airola K, Karonen T, Vaalamo M, et al: Expression of collagenases-1 and-3 and their inhibitors TIMP-1 and-3 correlates with the level of invasion in malignant melanomas. Br J Cancer 80: 733-743, 1999.
9. Heppner KJ, Matrisian LM, Jensen RA and Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149: 273-282, 1996.
10. Hilska M, Roberts PJ, Collan YU, et al: Prognostic significance of matrix metalloproteinases-1,-2,-7 and-13 and tissue inhibitors of metalloproteinases-1,-2,-3 and-4 in colorectal cancer. Int J Cancer 121: 714-723, 2007.
11. Mori D, Nakafusa Y, Miyazaki K and Tokunaga O: Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays. Pathol Res Pract 201: 777-789, 2005.
12. Roeb E, Arndt M, Jansen B, Schumpelick V and Matern S: Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1,-3, and-13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis 19: 518-524, 2004.
13. Fang YJ, Lu ZH, Wang GQ, et al: Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 24: 875-884, 2009.
14. Leeman MF, McKay JA and Murray GI: Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 55: 758-762, 2002.
15. Masaki T, Matsuoka H, Sugiyama M, et al: Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 84: 1317-1321, 2001.
16. Yamada T, Oshima T, Yoshihara K, et al: Overexpression of MMP-13 gene in colorectal cancer with liver metastasis. Anticancer Res 30: 2693-2699, 2010.
17. Ilvesaro JM, Merrell MA, Li L, et al: Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 6: 1534-1543, 2008.
18. Ilvesaro JM, Merrell MA, Swain TM, et al: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67: 774-781, 2007.
19. Merrell MA, Ilvesaro JM, Lehtonen N, et al: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4: 437-447, 2006.
20. Nurmenniemi S, Kuvaja P, Lehtonen S, et al: Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13. Exp Cell Res 316: 2676-2682, 2010.
21. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
22. Hemmi H, Takeuchi O, Kawai T, et al: A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745, 2000.
23. Latz E, Visintin A, Espevik T and Golenbock DT: Mechanisms of TLR9 activation. J Endotoxin Res 10: 406-412, 2004.
24. Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M and Klinman DM: Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 16: 17-22, 2004.
25. Chen JM, Nelson FC, Levin JI, et al: Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular desing. J Am Chem Soc 122: 9648-9654, 2000.
26. Koblinski JE, Ahram M and Sloane BF: Unraveling the role of proteases in cancer. Clin Chim Acta 291: 113-135, 2000.
27. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
28. Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9: 541-573, 1993.
29. Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34, 2006.
30. Inoue A, Takahashi H, Harada H, et al: Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity. Int J Oncol 37: 1121-1131, 2010.
31. Yong HY, Kim IY, Kim JS and Moon A: ErbB2-enhanced invasiveness of H-Ras MCF10A breast cells requires MMP-13 and uPA upregulation via p38 MAPK signaling. Int J Oncol 36: 501-507, 2010.
32. Rath T, Roderfeld M, Graf J, et al: Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis 12: 1025-1035, 2006.
33. Kawai T and Akira S: The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384, 2010.
34. Bowman CC, Rasley A, Tranguch SL and Marriott I: Cultured astrocytes express toll-like receptors for bacterial products. Glia 43: 281-291, 2003.
35. Droemann D, Albrecht D, Gerdes J, et al: Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 6: 1, 2005.
36. Platz J, Beisswenger C, Dalpke A, et al: Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 173: 1219-1223, 2004.
37. Schmausser B, Andrulis M, Endrich S, et al: Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 136: 521-526, 2004.
38. Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK and Eck M: Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 295: 179-185, 2005.
39. Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392, 2002.
40. Parks WC, Wilson CL and Lopez-Boado YS: Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4: 617-629, 2004.
41. Rath T, Roderfeld M, Graf J and Roeb E: [Matrix metalloproteinases in inflammatory bowel disease-from basic research to clinical significance]. Z Gastroenterol 47: 758-769, 2009.
42. Rath T, Roderfeld M, Halwe JM, Tschuschner A, Roeb E and Graf J: Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis. Scand J Gastroenterol 45: 1186-1196, 2010.